Angelo Antonini, K Ray Chaudhuri, Josefa Domingos, Joohi Jimenez-Shahed, Jack Wright, Connie H Yan, Ali Alobaidi, Lars Bergmann, Koray Onuk, Linda Harmer, Irene A Malaty
{"title":"对有关 \"5-2-1 标准能识别晚期帕金森病患者吗?7 个国家中 5-2-1 阳性患者的实际筛查准确性和负担 \"的回复。","authors":"Angelo Antonini, K Ray Chaudhuri, Josefa Domingos, Joohi Jimenez-Shahed, Jack Wright, Connie H Yan, Ali Alobaidi, Lars Bergmann, Koray Onuk, Linda Harmer, Irene A Malaty","doi":"10.1186/s12883-024-03691-3","DOIUrl":null,"url":null,"abstract":"<p><p>The 5-2-1 criteria was developed to facilitate the identification and referral of patients with Parkinson's Disease (PD) inadequately controlled by oral medications. The criterion was not developed to screen patients with PD for device-aided therapy eligibility. The robust design and validation of the 5-2-1 criteria minimizes over or inappropriate referrals, and supports physicians in the timely identification of patients with PD who may warrant further evaluation for treatment optimization. This response letter clarifies concerns raised by Moes et al.</p>","PeriodicalId":9170,"journal":{"name":"BMC Neurology","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290257/pdf/","citationCount":"0","resultStr":"{\"title\":\"Response to letter to the editor regarding \\\"Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries\\\".\",\"authors\":\"Angelo Antonini, K Ray Chaudhuri, Josefa Domingos, Joohi Jimenez-Shahed, Jack Wright, Connie H Yan, Ali Alobaidi, Lars Bergmann, Koray Onuk, Linda Harmer, Irene A Malaty\",\"doi\":\"10.1186/s12883-024-03691-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The 5-2-1 criteria was developed to facilitate the identification and referral of patients with Parkinson's Disease (PD) inadequately controlled by oral medications. The criterion was not developed to screen patients with PD for device-aided therapy eligibility. The robust design and validation of the 5-2-1 criteria minimizes over or inappropriate referrals, and supports physicians in the timely identification of patients with PD who may warrant further evaluation for treatment optimization. This response letter clarifies concerns raised by Moes et al.</p>\",\"PeriodicalId\":9170,\"journal\":{\"name\":\"BMC Neurology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290257/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12883-024-03691-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12883-024-03691-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
制定 5-2-1 标准是为了便于识别和转诊口服药物控制不佳的帕金森病 (PD) 患者。该标准并非用于筛选帕金森病患者是否符合器械辅助治疗的条件。5-2-1 标准的稳健设计和验证最大限度地减少了过度或不适当的转诊,并支持医生及时发现可能需要进一步评估以优化治疗的帕金森病患者。这封回复信澄清了 Moes 等人提出的疑虑。
Response to letter to the editor regarding "Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries".
The 5-2-1 criteria was developed to facilitate the identification and referral of patients with Parkinson's Disease (PD) inadequately controlled by oral medications. The criterion was not developed to screen patients with PD for device-aided therapy eligibility. The robust design and validation of the 5-2-1 criteria minimizes over or inappropriate referrals, and supports physicians in the timely identification of patients with PD who may warrant further evaluation for treatment optimization. This response letter clarifies concerns raised by Moes et al.
期刊介绍:
BMC Neurology is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of neurological disorders, as well as related molecular genetics, pathophysiology, and epidemiology.